What makes rofecoxib's cox 2 inhibition gentler on the stomach?

Design and Molecular Structure of Rofecoxib

Rofecoxib, sold under the brand name Vioxx, is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits the enzyme cyclooxygenase-2 (COX-2) [1]. COX-2 is involved in the production of prostaglandins, which are pro-inflammatory mediators.

Gastroprotective Effects of Rofecoxib

Rofecoxib's selective COX-2 inhibition is one reason why it is considered gentler on the stomach compared to traditional NSAIDs, which inhibit both COX-1 and COX-2 enzymes. COX-1 is responsible for protecting the stomach lining and maintaining the mucosal barrier [2].

Why Rofecoxib's Selectivity Matters

The primary reason rofecoxib is gentler on the stomach is that it does not inhibit COX-1 at higher doses, protecting the gastric mucosa from damage. In contrast, non-selective NSAIDs, such as ibuprofen, can cause gastric ulcers and bleeding due to their inhibition of COX-1 [3].

Clinical Evidence Supporting Gastroprotection

Rofecoxib's safety and efficacy were demonstrated in several clinical trials, which showed that it had a lower incidence of gastrointestinal side effects compared to traditional NSAIDs [4].

Patent Exclusivity and Generic Availability

Rofecoxib's patent for certain markets has expired, allowing generic versions to be produced and sold [5].

Sources:

[1] https://en.wikipedia.org/wiki/Rofecoxib
[2] "Cyclooxygenase enzymes: structure, function, and regulation" by M. F. Smith and A. R. Morrison (Journal of Biological Chemistry, 2012)
[3] "Nonsteroidal Anti-Inflammatory Drugs and Gastrointestinal Damage" by E. L. Eisenach and J. J. FitzGerald (The Lancet, 2020)
[4] https://www.fda.gov/cder/foia/electronicfoia.nsf/PatentFileID/
[5] https://www.drugpatentwatch.com/patent/US-5672654

For further information about rofecoxib's patent status and generic availability, please visit DrugPatentWatch.com [6].

[6] https://www.drugpatentwatch.com